Arcus Biosciences price target raised to $29 from $25 at Barclays

Oct 25, 2024 · Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on the shares. While the HIF2alpha …

$29
OFF

Arcus Biosciences Price Target Raised To $29 From $25 At Barclays

2 weeks from now

Oct 25, 2024 · Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on the shares. While the HIF2alpha …

nasdaq.com

$36.00
OFF

Barclays PLC Grows Position In Arcus Biosciences, Inc. (NYSE:RCUS)

2 weeks from now

Dec 28, 2024 · Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Barclays …

marketbeat.com

$29.00
OFF

Barclays Keeps Their Buy Rating On Arcus Biosciences (RCUS)

2 weeks from now

1 day ago · Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The company’s shares closed …

businessinsider.com

$25.00
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating

2 weeks from now

Dec 27, 2024 · Finally, Barclays increased their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Friday, October …

marketbeat.com

$36.00
OFF

Arcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low

2 weeks from now

2 days ago · Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Arcus Biosciences in a research note on Thursday, November 7th. Finally, Barclays lifted …

marketbeat.com

$25.00
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased By Barclays …

2 weeks from now

Dec 28, 2024 · Barclays lifted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. …

americanbankingnews.com

$25.00
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Given Average ... - ETF Daily …

2 weeks from now

Dec 27, 2024 · Barclays upped their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th.

etfdailynews.com

$25.00
OFF

RCUS Analyst Actions Repot For 10/25/2024 | News Quantified

2 weeks from now

Arcus Biosciences Inc Nyse Rcus Had Its Price Target Raised. 10/25/2024 Arcus Biosciences, Inc. (NYSE: RCUS) had its price target raised by analysts at Barclays PLC from $25.00 to …

newsquantified.com

$34.00
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Receives $34.00 Consensus …

2 weeks from now

Dec 5, 2024 · HC Wainwright reaffirmed a “neutral” rating and set a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Barclays upped their …

americanbankingnews.com

$25.00
OFF

Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price At …

2 weeks from now

Dec 5, 2024 · Barclays upped their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th.

etfdailynews.com

$34.00
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Receives $34.00 Consensus …

2 weeks from now

Dec 30, 2024 · Barclays increased their price target on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Wells …

americanbankingnews.com

$29
OFF

Arcus Biosciences Price Target Raised To $29 From $25 At Barclays

2 weeks from now

Oct 25, 2024 · Barclays analyst Peter Lawson raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps an Overweight rating on...

businessinsider.com

$25
OFF

Barclays Maintains Overweight On Arcus Biosciences, Raises Price …

2 weeks from now

Oct 25, 2024 · Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and raises the price target from $25 to $29.

sahmcapital.com

2%
OFF

Barclays Increases Arcus Biosciences (NYSE:RCUS) Price Target To …

2 weeks from now

Oct 25, 2024 · Despite a recent 4.2% drop in stock price, Arcus has shown a year-over-year revenue increase of 34.5%. The company focuses on developing cancer therapies and has …

longportapp.com

$29
OFF

Arcus Anti-TIGIT Antibody Differentiated From Roche’s, Says Barclays

2 weeks from now

Nov 27, 2024 · Barclays believes TIGIT "remains a show-me story at this point" and keeps an Overweight rating on Arcus with a $29 price target. The Arcus anti-TIGIT molecule is also …

nasdaq.com

$29.00
OFF

Barclays Sticks To Its Buy Rating For Arcus Biosciences (RCUS)

2 weeks from now

Nov 7, 2024 · Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00...

businessinsider.com

$25.00
OFF

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought By Jane Street …

2 weeks from now

Dec 20, 2024 · Barclays raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th.

etfdailynews.com

$34.00
OFF

Arcus Biosciences (RCUS) Stock Forecast And Price Target 2025

2 weeks from now

Jan 8, 2025 · According to the 9 analysts' twelve-month price targets for Arcus Biosciences, the average price target is $34.00. The highest price target for RCUS is $44.00, while the lowest …

marketbeat.com

FAQs about Arcus Biosciences price target raised to $29 from $25 at Barclays Coupon?

Is Arcus Biosciences a good buy?

Barclays upped their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Evercore ISI upgraded Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. View Our Latest Stock Report on Arcus Biosciences ...

How do I receive news & ratings for Arcus Biosciences?

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter. ...

Who owns Arcus Biosciences?

Finally, Intech Investment Management LLC acquired a new stake in shares of Arcus Biosciences in the third quarter worth approximately $244,000. Institutional investors and hedge funds own 92.89% of the company’s stock. NYSE:RCUS opened at $15.46 on Friday. ...

Which hedge funds have changed their positions in Arcus Biosciences?

Hedge funds have recently made changes to their positions in the business. Point72 Hong Kong Ltd acquired a new stake in shares of Arcus Biosciences during the 3rd quarter valued at $47,000. Innealta Capital LLC purchased a new position in Arcus Biosciences during the 2nd quarter worth approximately $66,000. ...

Did innealta capital acquire Arcus Biosciences?

Innealta Capital LLC acquired a new position in shares of Arcus Biosciences during the second quarter valued at approximately $66,000. Point72 DIFC Ltd acquired a new position in shares of Arcus Biosciences during the second quarter valued at approximately $83,000. ...

Does Jane Street Group own Arcus Biosciences?

Jane Street Group LLC raised its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 59.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 217,041 shares of the company’s stock after acquiring an additional 81,193 shares during the quarter. ...